City of Berkeley and Bayer Corporation - Bayer Healthcare ...

8
site Development 2009
Development Agreement Article 3 AnD exhibits c, D, AnD e; 1999 AmenDment
“ The broad scope of the long-range site development program contemplated
by [Bayer], combined with the long-term planning horizon needed for the
development of new pharmaceutical products, necessitates a reciprocal long-term
commitment by City to provide a sufficient degree of certainty in the land use
regulatory process to justify the massive financial investment associated with
the Project.”
–Development Agreement, pAge 5
Bayer has made a major investment in its Berkeley site since 1992. Site development to
date has earned Bayer a national Urban Design Award of Excellence from the American
Institute of Architects. More locally, Bayer has received an Award of Excellence from
Berkeley Design Advocates for the design of Building 60.
In 2009 the Berkeley site continued to accommodate all steps in the biotech operations
process including product engineering and process development, procurement, cell
fermentation, purification, sterile fill/freeze drying, packaging, warehousing, rigorous
quality assurance and quality control, and corporate administration. This year’s
$100 million investment decision ensures that all these operations will continue at the
Berkeley site.
As the 2009 Berkeley investment decision illustrated, site development is a complex
process. All decisions are initiated and approved by Bayer’s Governing Board in
Germany, and compete for resources with other Bayer facilities operating through
350 companies on five continents. Decisions are constrained by cost and operational
competitiveness as well as rapid developments in biotech manufacturing, balanced
against the time required to bring new buildings into compliance with strict technical
and regulatory imperatives. In the fast changing context in which today’s biotech
company operates, enormously expensive buildings may be obsolete within just one or
two decades.
long-teRm sIte Development goAls
Bayer’s Site Master Plan identifies a continuous reconfiguring of the site to meet four
key long-term goals:
• improved logistics: “the site currently includes facilities that are not located for
functional efficiencies or logistics; operations that are fragmented, with related
staff scattered across the campus; and circulation patterns that do not create a safe,
inviting, collegial atmosphere.”
• better efficiency: “buildings which are beyond their useful life or no longer meet
current functional requirements should be replaced in appropriate locations.”